Treatment potentials for diabetic retinopathy with angiogenesis inhibitors (review)

2021 ◽  
pp. 55-57
Author(s):  
M.M. Bikbov ◽  
◽  
R.M. Zainullin ◽  
L.I. Gilemzyanova ◽  
◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Diabetic Retinopathy ◽  
Growth Factor ◽  
Macular Edema ◽  
Key Words ◽  
Intravitreal Injection ◽  
Clinical Studies ◽  
Angiogenesis Inhibitors ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Diabetic retinopathy is one of the socially significant problems in world ophthalmology due to a significant decrease in visual functions and patient disability. This article presents recent clinical studies on the treatment with angiogenesis inhibitors of nonproliferative and proliferative diabetic retinopathy with and without diabetic macular edema. Key words: diabetic retinopathy, intravitreal injection, angiogenesis inhibitors, vascular endothelial growth factor.

scholarly journals Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0247161
Author(s):  
Ameay V. Naravane ◽  
Rusdeep Mundae ◽  
Yujia Zhou ◽  
Christopher Santilli ◽  
Frederik J. G. M. van Kuijk ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Diabetic Retinopathy ◽  
Pilot Study ◽  
Growth Factor ◽  
Macular Edema ◽  
Age Related Macular Degeneration ◽  
Vascular Endothelial ◽  
Anti Vegf ◽  
Delayed Group ◽  
Endothelial Growth Factor

Regularly scheduled intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are essential to maintaining and/or improving many ocular conditions including: neovascular age-related macular degeneration (nAMD), diabetic retinopathy, and retinal vein occlusions with macular edema (RVO). This study aims to assess the effect of unintended delays in anti-VEGF treatment during the first wave of the COVID-19 pandemic. This retrospective case series identified patients receiving regularly scheduled anti-VEGF intravitreal injections based on current procedural terminology (CPT) code at two practices in Minnesota. Diagnoses were limited to nAMD, diabetic macular edema (DME), proliferative diabetic retinopathy, and RVO. Patients were divided into two groups based on whether they maintained or delayed their follow-up visit by more than two weeks beyond the recommended treatment interval during the COVID-19 lockdown. The ‘COVID-19 lockdown’ was defined as the period after March, 28th, 2020, when a lockdown was declared in Minnesota. We then compared the visual acuity and structural changes to the retina using ocular coherence tomography (OCT) to assess whether delayed treatment resulted in worse visual outcomes. A total of 167 eyes from 117 patients met criteria for inclusion in this study. In the delayed group, the average BCVA at the pre- and post-lockdown visits were 0.614 and 0.715 (logMAR) respectively (p = 0.007). Central subfield thickness (CST) increased from 341 to 447 in the DME delayed group (p = 0.03) while the CST increased from 301 to 314 (p = 0.4) in the nAMD delayed group. The results of this pilot study suggests that treatment delays may have a negative impact on the visual and anatomic outcomes of patients with nAMD and DME. Future studies with larger sample sizes are required for further investigation.

New Development and New Medicine in Treatment of Diabetic Retinopathy and Diabetic Macular Edema

2018 ◽  
pp. 185-188
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Diabetic Retinopathy ◽  
Growth Factor ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Vascular Endothelial ◽  
New Development ◽  
Endothelial Growth Factor ◽  
Hallmark Feature

The blood-retina barrier alteration is a hallmark feature of diabetic retinopathy. The vascular endothelial growth factor is an important vasopermeability factor that playing role in the pathogenesis of blood-retina barrier destruction. Inflammation is the second pathology in diabetic retinopathy. New researches are ongoing about both pathways for diabetic retinopathy and macular edema therapy.

scholarly journals Concomitant Bilateral Intravitreal Injection of Anti-Vascular Endothelial Growth Factor: Experience in Covid-19 Pandemic

2021 ◽  
Author(s):  
SERKAN ÖZEN ◽  
Hakan Koc ◽  
Hasan Burhanettin Kaptı ◽  
Murat Atabey Ozer
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Adverse Events ◽  
Macular Edema ◽  
Intravitreal Injection ◽  
Vascular Endothelial ◽  
Anti Vegf ◽  
Before And After ◽  
The Mean ◽  
Endothelial Growth Factor

Abstract Purpose: To report the concomitant bilateral intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection preference rates of patients before and after the Covid-19 outbreak and to evaluate whether this practice is safe when compared to unilateral injection. Materials and Methods: This is a single-center, retrospective study including consecutive series of 198 eyes of 112 patients received bilateral same-day (concomitant) or unilateral anti-VEGF injections of bevacizumab, ranibizumab, and aflibercept in the operating-room between January 2020 and January 2021. One-year medical record data including preference of bilateral over unilateral injection and adverse events were reviewed with 3-month intervals as before and after Covid-19 pandemic due to the labile Covid-19 outbreak course.Results: A total of 504 injections with 234 concomitant bilateral (%46) were administered to 112 patients. The study group consisted of 58 neovascular age-related macular degeneration (nAMD- 63.7% had bilateral nAMD), 46 diabetic macular edema (DME- 67.3% had bilateral DME) and 8 macular edema complicating retinal vein occlusion (RVO- 25% had bilateral RVO) patients. Of the injections, 156 (31%) were bevacizumab, 144 (29%) were aflibercept, and 204 (40%) were ranibizumab. The mean follow-up time per patient was 7.4 ± 4.3 months (range 4-11 months) and the mean number of injections was 3.6 ± 2.1 (range 2-10). None of the patients experienced serious vision-threatening complications or non-ocular adverse events. 85% of patients whose both eyes involved strongly preferred concomitant bilateral injection during Covid-19 pandemic while it was %35 before Covid-19 (P<0.001). The ratio of the number of concomitant bilateral injections to a total of injections increased from 30% to 57% after Covid-19 (P=0.03). Only 3 patients (2.6%) requested alternating unilateral injections after receiving the second concomitant bilateral injections.Conclusion: Concomitant bilateral injection approach was preferred by the majority of patients and did not increase the adverse event rate when applied under meticulous precautions; This intravitreal injection option may be preferred during still ongoing pandemic to reduce the clinical visits of patients at risk of Covid-19 related mortality due to their comorbidities and age.

scholarly journals Diabetic macular edema: it is more than just VEGF

F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 1019 ◽  
Author(s):  
Michael A. Singer ◽  
Daniel S. Kermany ◽  
Jana Waters ◽  
Michael E. Jansen ◽  
Lyndon Tyler
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Diabetic Retinopathy ◽  
Growth Factor ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Vascular Endothelial ◽  
Treatment Burden ◽  
Current Therapies ◽  
History Of ◽  
Endothelial Growth Factor

Diabetic macular edema is a serious visual complication of diabetic retinopathy. This article reviews the history of previous and current therapies, including laser therapy, anti-vascular endothelial growth factor agents, and corticosteroids, that have been used to treat this condition. In addition, it proposes new ways to use them in combination in order to decrease treatment burden and potentially address other causes besides vascular endothelial growth factor for diabetic macular edema.

Sign in / Sign up

Export Citation Format

Share Document